161 related articles for article (PubMed ID: 35240257)
1. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
Gene; 2022 May; 823():146382. PubMed ID: 35240257
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the rs3088442 G>A SLC22A3 Gene Polymorphism and the Role of microRNA 147 in Groups of Adult Pakistani Populations With Type 2 Diabetes in Response to Metformin.
Moeez S; Riaz S; Masood N; Kanwal N; Arif MA; Niazi R; Khalid S
Can J Diabetes; 2019 Mar; 43(2):128-135.e3. PubMed ID: 30297296
[TBL] [Abstract][Full Text] [Related]
3. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
[TBL] [Abstract][Full Text] [Related]
4. The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.
Mahrooz A; Parsanasab H; Hashemi-Soteh MB; Kashi Z; Bahar A; Alizadeh A; Mozayeni M
Clin Exp Med; 2015 May; 15(2):159-65. PubMed ID: 24740684
[TBL] [Abstract][Full Text] [Related]
5. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
[TBL] [Abstract][Full Text] [Related]
6. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
[TBL] [Abstract][Full Text] [Related]
8. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
[TBL] [Abstract][Full Text] [Related]
9. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
Liang H; Xu W; Zhou L; Yang W; Weng J
Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
[TBL] [Abstract][Full Text] [Related]
10. The association study between changes in HbA1C with rs2250486 and rs67238751 genetic variants for SLC47A1 in newly diagnosed Iranian patients with type 2 diabetes mellitus: 6 months follow-up study.
Semnani A; Kazerouni F; Kalbasi S; Shahrokhi SZ; Rahimipour A
Endocrinol Diabetes Metab; 2023 May; 6(3):e410. PubMed ID: 36786075
[TBL] [Abstract][Full Text] [Related]
11. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
[TBL] [Abstract][Full Text] [Related]
12. A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.
Goswami S; Yee SW; Xu F; Sridhar SB; Mosley JD; Takahashi A; Kubo M; Maeda S; Davis RL; Roden DM; Hedderson MM; Giacomini KM; Savic RM
Clin Pharmacol Ther; 2016 Nov; 100(5):537-547. PubMed ID: 27415606
[TBL] [Abstract][Full Text] [Related]
13. Effects of SLC22A2 (rs201919874) and SLC47A2 (rs138244461) genetic variants on Metformin Pharmacokinetics in Pakistani T2DM patients.
Moeez S; Khalid Z; Jalil F; Irfan M; Ismail M; Arif MA; Niazi R; Khalid S
J Pak Med Assoc; 2019 Feb; 69(2):155-163. PubMed ID: 30804576
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
15. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.
Kim H; Bae S; Yoon HY; Yee J; Gwak HS
J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
[TBL] [Abstract][Full Text] [Related]
17. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
[TBL] [Abstract][Full Text] [Related]
19. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
